Denmark· DK-28106443520
Onureg
A azacitidine product containing azacitidin, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 18 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Azacitidine is registered in 18 of 19 countries.
Countries holding a registration under ATC L01BC07 (azacitidine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Azacitidine · ATC L01BC07
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of azacitidine costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.69 in France to $470.17 in Switzerland — a ×683 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Azacitidine · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$470.17
- CZ Czechia$4.72
- FR France$0.69
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- AZACITIDIN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L01BC07
- ATC class
- Azacitidine
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106443520
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for azacitidine.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Azacitidine · interactions on record
75 records
- 30 severe
- 45 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01BC07
Azacitidine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fee06a9b-e8ea-44d2-80de-6742ab80aff5 GET /v1/drugs/fee06a9b-e8ea-44d2-80de-6742ab80aff5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "300 mg",
"auth_role": "MOD",
"dk_drugid": "28106443520",
"substance": "AZACITIDIN",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44364"
}See everything about azacitidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.